<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1286</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10954526</PubmedId>
            <Abstract>CD8(+) T-cell responses can be induced by DNA immunization, but little is known about the kinetics of these responses in vivo in the absence of restimulation or how soon protective immunity is conferred by a DNA vaccine. It is also unclear if CD8(+) T cells primed by DNA vaccines express the vigorous effector functions characteristic of cells primed by natural infection or by immunization with a recombinant live virus vaccine. To address these issues, we have used the sensitive technique of intracellular cytokine staining to carry out direct ex vivo kinetic and phenotypic analyses of antigen-specific CD8(+) T cells present in the spleens of mice at various times after (i) a single intramuscular administration of a plasmid expressing the nucleoprotein (NP) gene from lymphocytic choriomeningitis virus (LCMV), (ii) infection by a recombinant vaccinia virus carrying the same protein (vvNP), or (iii) LCMV infection. In addition, we have evaluated the rapidity with which protective immunity against both lethal and sublethal LCMV infections is achieved following DNA vaccination. The CD8(+) T-cell response in DNA-vaccinated mice was slightly delayed compared to LCMV or vvNP vaccinees, peaking at 15 days postimmunization. Interestingly, the percentage of antigen-specific CD8(+) T cells present in the spleen at day 15 and later time points was similar to that observed following vvNP infection. T cells primed by DNA vaccination or by infection exhibited similar cytokine expression profiles and had similar avidities for an immunodominant cytotoxic T lymphocyte epitope peptide, implying that the responses induced by DNA vaccination differ quantitatively but not qualitatively from those induced by live virus infection. Surprisingly, protection from both lethal and sublethal LCMV infections was conferred within 1 week of DNA vaccination, well before the peak of the CD8(+) T-cell response.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>8286-91</ArticlePages>
            <ArticleTitle>Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Hassett</LastName>
                    <ForeName>D E</ForeName>
                </Author>
                <Author>
                    <LastName>Slifka</LastName>
                    <ForeName>M K</ForeName>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Whitton</LastName>
                    <ForeName>J L</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Neuropharmacology, Scripps Research Institute, La Jolla, California 92037, USA. dhassett@scripps.edu.</Affiliations>
            <ArticleChemicalList>Cytokines;Nucleoproteins;Peptide Fragments;Vaccines, DNA;Viral Proteins;Viral Vaccines;nucleoprotein peptide 118-126, lymphocytic choriomeningitis virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; CD8-Positive T-Lymphocytes(immunology; metabolism); Cytokines(metabolism); Cytotoxicity, Immunologic; Injections, Intramuscular; Lymphocytic Choriomeningitis(immunology; mortality; prevention &amp; control); Lymphocytic choriomeningitis virus(genetics; immunology; metabolism); Mice; Mice, Inbred BALB C; Nucleoproteins(genetics; immunology; metabolism); Peptide Fragments(genetics; immunology; metabolism); Spleen(immunology); Vaccines, DNA(administration &amp; dosage; immunology); Vaccinia virus(immunology); Viral Proteins(genetics; immunology; metabolism); Viral Vaccines(administration &amp; dosage; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>74</Volume>
                <Issue>18</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP 118-126</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RPQASGVYM</LinearSequence>
                        <StartingPosition>118</StartingPosition>
                        <EndingPosition>126</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P07400.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11623</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>55289</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2 and 3</LocationOfData>
                        <TCellId>18999</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>4-16 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P07400.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Nucleocapsid protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 200000 pfu</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>169</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 118-126</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RPQASGVYM</LinearSequence>
                                        <StartingPosition>118</StartingPosition>
                                        <EndingPosition>126</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P07400.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>57</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Epitope-specific CD8+ T-cells peaked at 7 days post-immunization. These cells produced TNFα at later stages of the infection with &gt;90% of the cell population becoming IFNγ+ TNFα+ by 30 days and showed the same avidity for the epitope as cells from LCMV-infected mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4A</LocationOfData>
                        <TCellId>19012</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>4-16 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P07400.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Nucleocapsid protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose(s) of 2 ug/ul DNA vaccine in saline</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Each mouse received 200 ug of the DNA vaccine bilaterally 2 (50 ul each injection) into the anterior tibial muscles and challenged 1 week later with 200000 pfu LCMV intraperitoneally.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>169</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -MHC subset identification</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 118-126</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RPQASGVYM</LinearSequence>
                                        <StartingPosition>118</StartingPosition>
                                        <EndingPosition>126</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P07400.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Splenocytes from pCMVNP-immunized and LCMV-challenged mice displayed killing activity against target cells primed with the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2 and 3</LocationOfData>
                        <TCellId>18994</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>4-16 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 200000 pfu</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>169</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 118-126</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RPQASGVYM</LinearSequence>
                                        <StartingPosition>118</StartingPosition>
                                        <EndingPosition>126</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P07400.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Epitope-specific CD8+ T-cells peaked at 7 days post-immunization. These cells also produced TNFα at later stages of the infection with &gt;90% of the cell population becoming IFNγ+ TNFα+ by 30 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2 and 3</LocationOfData>
                        <TCellId>18993</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>4-16 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P07400.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Nucleocapsid protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose(s) of 2 ug/ul DNA vaccine in saline</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Each mouse received 200 ug of the DNA vaccine bilaterally (50 ul each injection) into the anterior tibial muscles.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>169</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 118-126</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RPQASGVYM</LinearSequence>
                                        <StartingPosition>118</StartingPosition>
                                        <EndingPosition>126</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P07400.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Epitope-specific CD8+ T-cells peaked at 15 days post-immunization. These cells also produced TNFα at later stages of the infection with &gt;90% of the cell population becoming IFNγ+ TNFa+ by 30 days and showed the same avidity for the epitope as cells from LCMV-infected mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

